- cafead   Nov 21, 2023 at 12:02: PM
via BeiGene on Tuesday announced that it would acquire an exclusive global license to Ensem Therapeutics’ investigational and potentially best-in-class oral CDK2 inhibitor EXT-197, which is being developed for cancer.
article source
article source